16Apr 2024

MOLECULAR CLASSIFICATION OF BREAST CANCER WITH IMMUNOHISTOCHEMICAL MARKERS

  • Postgraduate Resident, Department of Pathology, Dr. Balasaheb Vikhe Patil Rural Medical College, Pravara Institute of Medical Sciences, Deemed to be University, Loni.
  • Professor and Head of Department, Department of Pathology, Dr. Balasaheb Vikhe Patil Rural Medical College, Pravara Institute of Medical Sciences, Deemed to be University, Loni.
  • Professor, Department of Pathology, Dr. Balasaheb Vikhe Patil Rural Medical College, Pravara Institute of Medical Sciences, Deemed to be University, Loni.
Crossref Cited-by Linking logo
  • Abstract
  • Cite This Article as
  • Corresponding Author

Introduction: Breast cancer is one of major cause of female mortality worldwide. The molecular classification has considered to mainly aid clinicians to better approach the prognosis and also to formulate treatments for different prognosis. According to St.Gallen symposia, five intrinsic subtypes are established: luminal A-like, luminal B-like, HER2 positive & triple negative. The aim of study is to classify carcinoma of breast into molecular classes using IHC markers in carcinoma breast.

Material & Methods: This is descriptive, cross sectional study. Histologically diagnosed cases of carcinoma of breast by H&E stain were stained by IHC markers ER, PR, HER 2/neu, ki67 & CK5/6 & interpreted. Result and Discussion-Out of 134 cases diagnosed as carcinoma breast,120 cases belongs to IDC, NST subtype. Maximum cases were from age group of 41-60 years. Grade II was most commonly seen among the total cases in present study followed by grade 3 and grade 1 respectively. HER 2 enriched provides better therapeutic options like treatment with Herceptin for HER2/neu positive cases.

Conclusion: The molecular classification using IHC surrogate markers showed more number of cases in subtype HER2(+) Enriched, luminal B, Her2(+) and triple negative. 


[Yogita Gadekar, S.D Dongre and Bharti Baviskar (2024); MOLECULAR CLASSIFICATION OF BREAST CANCER WITH IMMUNOHISTOCHEMICAL MARKERS Int. J. of Adv. Res. (Apr). 852-857] (ISSN 2320-5407). www.journalijar.com


Dr.Yogita Gadekar
Junior Resident Pravara Institute of medical sciences,Loni.
India

DOI:


Article DOI: 10.21474/IJAR01/18624      
DOI URL: http://dx.doi.org/10.21474/IJAR01/18624